KR101931489B1 - 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법 - Google Patents

칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법 Download PDF

Info

Publication number
KR101931489B1
KR101931489B1 KR1020167023724A KR20167023724A KR101931489B1 KR 101931489 B1 KR101931489 B1 KR 101931489B1 KR 1020167023724 A KR1020167023724 A KR 1020167023724A KR 20167023724 A KR20167023724 A KR 20167023724A KR 101931489 B1 KR101931489 B1 KR 101931489B1
Authority
KR
South Korea
Prior art keywords
angiotensin
antagonist
receptor antagonist
calcium antagonist
calcium
Prior art date
Application number
KR1020167023724A
Other languages
English (en)
Korean (ko)
Other versions
KR20160105543A (ko
Inventor
이치로 하라
유키코 다나카
히로유키 히구치
아키코 데라모토
도모야 오노시타
Original Assignee
이에이 파마 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이에이 파마 가부시키가이샤 filed Critical 이에이 파마 가부시키가이샤
Publication of KR20160105543A publication Critical patent/KR20160105543A/ko
Application granted granted Critical
Publication of KR101931489B1 publication Critical patent/KR101931489B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020167023724A 2012-10-12 2013-10-11 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법 KR101931489B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2012-226984 2012-10-12
JP2012226984 2012-10-12
PCT/JP2013/077730 WO2014058047A1 (ja) 2012-10-12 2013-10-11 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012315A Division KR101778050B1 (ko) 2012-10-12 2013-10-11 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법

Publications (2)

Publication Number Publication Date
KR20160105543A KR20160105543A (ko) 2016-09-06
KR101931489B1 true KR101931489B1 (ko) 2018-12-24

Family

ID=50477509

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020157012315A KR101778050B1 (ko) 2012-10-12 2013-10-11 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
KR1020167023724A KR101931489B1 (ko) 2012-10-12 2013-10-11 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020157012315A KR101778050B1 (ko) 2012-10-12 2013-10-11 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법

Country Status (4)

Country Link
JP (2) JP5790965B2 (ja)
KR (2) KR101778050B1 (ja)
TW (1) TW201427720A (ja)
WO (1) WO2014058047A1 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014058046A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤
JP6843498B2 (ja) * 2015-10-14 2021-03-17 Ｅａファーマ株式会社 錠剤、固体分散体顆粒及びその製造方法
JP6967833B2 (ja) * 2015-11-30 2021-11-17 大原薬品工業株式会社 医薬品包装箱を利用した、配合錠の両面印字情報の提供方法
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
KR101769293B1 (ko) * 2016-09-30 2017-08-30 주식회사 종근당 칸데사르탄 및 암로디핀을 포함하는 단일층으로 이루어진 복합제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175942A1 (en) 2006-09-15 2009-07-09 Daiichi Sankyo Company, Limited Solid Dosage Form of Olmesartan Medoxomil And Amlodipine

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9416599D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
JP3415291B2 (ja) * 1994-09-27 2003-06-09 味の素ファルマ株式会社 重炭酸透析用剤
ES2351249T3 (es) * 2001-07-27 2011-02-02 Astellas Pharma Inc. Composición que comprende partículas finas, de liberación sostenida, para comprimidos de disgregación rápida en la cavidad bucal.
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
JP5063370B2 (ja) * 2005-06-27 2012-10-31 第一三共株式会社 湿式造粒製薬の調製方法
US20080279942A1 (en) * 2005-06-27 2008-11-13 Takeshi Hamaura Pharmaceutical Preparation Containing an Angiotensin II Receptor Antagonist and a Calcium Channel Blocker
GT200600371A (es) * 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
PE20120542A1 (es) * 2006-06-27 2012-05-14 Novartis Ag Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas
JPWO2008016171A1 (ja) * 2006-08-04 2009-12-24 味の素株式会社 腎機能障害予防・治療剤
JP2008044871A (ja) * 2006-08-11 2008-02-28 Ajinomoto Co Inc 心血管疾患予防・治療剤
KR20100016093A (ko) * 2007-03-30 2010-02-12 아지노모토 가부시키가이샤 고체 분산체 제제
DE102008059206A1 (de) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
CN104958273B (zh) * 2009-05-27 2017-10-13 株式会社茶山医化 含有泡腾层的多层片

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175942A1 (en) 2006-09-15 2009-07-09 Daiichi Sankyo Company, Limited Solid Dosage Form of Olmesartan Medoxomil And Amlodipine

Also Published As

Publication number Publication date
JPWO2014058047A1 (ja) 2016-09-05
KR20160105543A (ko) 2016-09-06
TW201427720A (zh) 2014-07-16
JP2015003915A (ja) 2015-01-08
WO2014058047A1 (ja) 2014-04-17
JP6302802B2 (ja) 2018-03-28
KR101778050B1 (ko) 2017-09-13
JP5790965B2 (ja) 2015-10-07
KR20150065887A (ko) 2015-06-15

Similar Documents

Publication Publication Date Title
US11793809B2 (en) Pharmaceutical compositions of nilotinib
CA2338256C (en) Bioenhanced formulations comprising eprosartan in oral solid dosage form
US20020098241A1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
CA2801020A1 (en) A stable pharmaceutical formulation comprising telmisartan and hydrochlorothiazide
JP6041591B2 (ja) イルベサルタンとアムロジピンまたはその塩を含有する安定化された医薬組成物
KR101931489B1 (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
CA2644179C (en) Novel pharmaceutical composition comprising a disintegration matrix
KR101725462B1 (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제
AU757547B2 (en) Novel compositions of eprosartan
EP1033974B1 (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US20030022928A1 (en) Novel compositions of eprosartan
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
US20080182908A1 (en) Pharmaceutical compositions comprising memantine
US20150119317A1 (en) Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
MXPA00004791A (en) High drug load immediate and modified release oral dosage formulations and processes for their manufacture

Legal Events

Date Code Title Description
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant